



Attorney Docket No. 5573.210-US
Peschke et al.
Serial No. 09/356,313 Filed July 16, 1999
Express Mail Label No.: EV 246880584 US

Attorney Docket No.: 5573.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Peschke et al. Confirmation No.: 7669
Application No.: 09/356,313 Group Art Unit: 1653
Filed: July 16, 1999 Examiner: Lukton, David
For: Compounds With Growth Hormone Releasing Properties

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This amendment is timely submitted under 37 CFR §1.114 with a Request for Continued Examination (RCE) Transmittal, enclosed herewith.

The Corrected Notice of Allowance and Fee(s) Due mailed August 13, 2004, states the total fee(s) are due November 15, 2004.

The examiner states in the Notice of Allowability claims numbered 1-17 are allowed, however claims numbered 13, 14, 16 and 17 were withdrawn from consideration in the Office Action mailed September 10, 2002, paper number 8, without subsequent record of their rejoinder. Applicant respectfully requests rejoinder of previously withdrawn claims numbered 13, 14, 16 and 17.

Applicant has enclosed herewith an Information Disclosure Statement pursuant to 37 C.F.R. §§1.56, 1.97 and 1.98. It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein.

Pursuant to 37 C.F.R. §1.121, Applicant submits a complete listing of all of the claims ever presented for this pending application with current amendments noted.

Applicant has amended the specification and claims numbered 1, 4 and 12 herein.